<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="363899">
  <stage>Registered</stage>
  <submitdate>21/03/2013</submitdate>
  <approvaldate>25/03/2013</approvaldate>
  <actrnumber>ACTRN12613000327785</actrnumber>
  <trial_identification>
    <studytitle>Impact of pharmacogenomics and metabolism on the effectiveness and toxicity of racemic ketamine in palliative care and chronic pain patients</studytitle>
    <scientifictitle>Evaluation of the clinical pharmacology and pharmacogenomics of ketamine in palliative care patients and chronic pain patients</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Nil known</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Chronic pain patients</healthcondition>
    <conditioncode>
      <conditioncode1>Anaesthesiology</conditioncode1>
      <conditioncode2>Pain management</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Ketamine 24 hour continuous intravenous infusions of 100 (day 1), 300 (day 2) and 500 mg (day 3) per day over a total of 3 days in palliative medicine and 5 days (500 mg/day on day 4 and 5) in chronic pain patients. Total intervention is a maximum of 5 days.
Blood samples collected to assess pharmacokinetics, metabolism to norketamine, CYP2B6 genetic polymorphisms.
Relationship between plasma concentrations and a) pain scores and b) adverse effects </interventions>
    <comparator>No control group as this is a pharmacokinetic/pharmacogenomic study</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Treatment: Drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Relationship of plasma ketamine and/or norketamine concentrations to efficacy of pain attenuation (pain scores 100 mm VAS) and adverse effects (NCI Criteria especially  psychotomimetic)</outcome>
      <timepoint>Day 3</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Relationship of CYP2B6 polymorphism (*6 variant) to plasma ketamine and norketamine concentrations (LC-MS assay) using gene-dose test (Jonckheere-Terpstra) ; </outcome>
      <timepoint>end of days 1, 2 and /or 3</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Relationship of cytokine (Il-1B, IL-6) polymorphisms (SNP variants) to ketamine efficacy (VAS score) and adverse effects (psychotomimetic) using multivariate ANOVA..</outcome>
      <timepoint>Day 3 to 5</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Able to be commenced on ketamine based on clinical grounds for refractory cancer or other pain.
Fluent in english language.
Able to participate in the monitoring of pain and adverse effects
Males and females over 18 years</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>90</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Patients with poor venous access
patients in whom significant hypertension or tachycardia would be potentially dangerous
Adverse reaction to ketamine in the past</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment>Patients for whom ketamine is indicated on clinical grounds</concealment>
    <sequence>no randomisation as the study is investigating ketamine clinical pharmacology per se and the drug is being used on clinical grounds </sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate>29/08/2012</anticipatedstartdate>
    <actualstartdate>17/10/2012</actualstartdate>
    <anticipatedenddate>18/12/2013</anticipatedenddate>
    <actualenddate />
    <samplesize>50</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Andrew Somogyi</primarysponsorname>
    <primarysponsoraddress>Discipline of Pharmacology
School of Medical Sciences
University of Adelaide
Frome Road
Adelaide 5005
South Australia</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Self funded/Unfunded</fundingtype>
      <fundingname>Andrew Somogyi</fundingname>
      <fundingaddress>Discipline of Pharmacology
School of Medical Sciences
University of Adelaide
Frome Road
Adelaide 5005
South Australia</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Individual</sponsortype>
      <sponsorname>Associate Prof Kate Jackson</sponsorname>
      <sponsoraddress>Palliative Care
McCulloch House
Monash Medical Centre
246 Clayton Road
Clayton
Victoria 3168</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The primary purpose is to determine whether the effectiveness of ketamine and its toxicity are related to the circulating plasma concentrations of ketamine and/or its active metabolite norketamine.
The study hypothesis is that there is a plasma concentration window for ketamine, below which it is ineffective to control pain and above which it produces adverse effects, and that the concentration is dependent on the patient's genotype for CYP2B6</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Southern Health HREC</ethicname>
      <ethicaddress>246 Clayton Road
Clayton 3168
Victoria</ethicaddress>
      <ethicapprovaldate>24/07/2012</ethicapprovaldate>
      <hrec>12159L</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>A/Prof</title>
      <name>Kate Jackson</name>
      <address>Supportive and Palliative Care Unit
McCulloch House
Monash Medical Centre
246 Clayton Road 
Clayton, 3168
Victoria</address>
      <phone>+61 03 9594 5347</phone>
      <fax />
      <email>kate.jackson@southernhealth.org.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>A/Prof</title>
      <name>Kate Jackson</name>
      <address>Supportive and Palliative Care Unit
McCulloch House
Monash Medical Centre
246 Clayton Road 
Clayton, 3168
Victoria</address>
      <phone>+61 03 9594 5347</phone>
      <fax />
      <email>kate.jackson@southernhealth.org.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Andrew Somogyi</name>
      <address>Discipline of Pharmacology
Faculty of Health Sciences
University of Adelaide
Adelaide 5005
South Australia</address>
      <phone>+ 61 8 83135572</phone>
      <fax />
      <email>andrew.somogyi@adelaide.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Andrew Somogyi</name>
      <address>Discipline of Pharmacology
Faculty of Health Sciences
University of Adelaide
Adelaide 5005</address>
      <phone />
      <fax />
      <email />
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>